Log in to your Inderes Free account to see all free content on this page.
Magnasense
0.194 SEK -4.53%Be the first to follow this company
Magnasense operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.
Revenue
90K
EBIT %
-62,400 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
MAGNA
Daily low / high price
0.18 / 0.2
SEK
Market cap
9.54M SEK
Turnover
91.78K SEK
Volume
478K
Financial calendar
Interim report
15.11.2024
Annual report
28.03.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
CBNY-CityBank N.A | 16.7 % | 16.7 % |
Försäkringsbolaget Avanza Pension | 3.7 % | 3.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Magnasense AB calls for partial payment of Tranche 3 of SEK 2.50 million from Atlas Special Opportunities, LLC
Magnasense AB carries out previously announced directed share issue of 7,080,627 shares to Atlas Special Opportunities following called upon conversions of SEK 2.50 million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio